Literature DB >> 23412363

Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups.

Andrea Elizabeth DePetris1, Benjamin L Cook.   

Abstract

OBJECTIVE Numerous articles have identified that medical technologies diffuse more rapidly among non-Latino whites compared with other racial-ethnic groups. However, whether health risk warnings also diffuse differentially across racial-ethnic minority groups is uncertain. This study assessed racial-ethnic variation in children's antidepressant use before and after the 2004 black-box warning concerning risks of antidepressants for youths. METHODS Data consisted of responses for white, black, and Latino youths ages five through 17 from the 2002-2008 Medical Expenditure Panel Survey (N=44,422). The dependent variable was any antidepressant use in the prior year. Independent variables were race-ethnicity, year, psychological impairment, income, insurance status, region, and parents' education level. Logistic regression models were used to assess antidepressant use conditional on race-ethnicity, time, interaction between race-ethnicity and time, need, socioeconomic status, and Institute of Medicine-concordant estimates of disparities in predicted antidepressant use before and after the warning. RESULTS The warnings affected antidepressant use differentially for whites, blacks, and Latinos. Usage rates among whites decreased from 3.3 to 2.1 percentage points between prewarning and postwarning, whereas usage rates remained steady among Latinos and increased among blacks. Findings were significant in multiple regression analyses, in which predictions were adjusted for need. CONCLUSIONS The findings indicate that health safety information on antidepressant usage among children diffused faster among whites than nonwhites, suggesting the need to improve infrastructure for delivering important health messages to racial-ethnic minority populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412363      PMCID: PMC3686566          DOI: 10.1176/appi.ps.201200087

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  37 in total

1.  Does Medicare managed care provide equal treatment for mental illness across races?

Authors:  Beth Virnig; Zhen Huang; Nicole Lurie; Dorothea Musgrave; A Marshall McBean; Bryan Dowd
Journal:  Arch Gen Psychiatry       Date:  2004-02

2.  Physician accessibility: an urban case study of pediatric providers.

Authors:  Mark F Guagliardo; Cynthia R Ronzio; Ivan Cheung; Elizabeth Chacko; Jill G Joseph
Journal:  Health Place       Date:  2004-09       Impact factor: 4.078

3.  Racial and ethnic disparities in SSRI availability in substance abuse treatment.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

4.  Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites.

Authors:  Junling Wang; Jason M Noel; Ilene H Zuckerman; Nancy A Miller; Fadia T Shaya; C Daniel Mullins
Journal:  Med Care Res Rev       Date:  2006-12       Impact factor: 3.929

5.  Are minority children the last to benefit from a new technology? Technology diffusion and inhaled corticosteriods for asthma.

Authors:  Timothy G Ferris; Karen Kuhlthau; John Ausiello; James Perrin; Robert Kahn
Journal:  Med Care       Date:  2006-01       Impact factor: 2.983

Review 6.  Handling missing data in survey research.

Authors:  J M Brick; G Kalton
Journal:  Stat Methods Med Res       Date:  1996-09       Impact factor: 3.021

7.  Racial and ethnic differences in utilization of mental health services among high-risk youths.

Authors:  Ann F Garland; Anna S Lau; May Yeh; Kristen M McCabe; Richard L Hough; John A Landsverk
Journal:  Am J Psychiatry       Date:  2005-07       Impact factor: 18.112

8.  Racial and ethnic disparities in early childhood health and health care.

Authors:  Glenn Flores; Lynn Olson; Sandra C Tomany-Korman
Journal:  Pediatrics       Date:  2005-02       Impact factor: 7.124

9.  Perspectives on disparities in depression care.

Authors:  Robert E Kristofco; Altha J Stewart; William Vega
Journal:  J Contin Educ Health Prof       Date:  2007       Impact factor: 1.355

10.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more
  8 in total

1.  Quality of follow-up after hospitalization for mental illness among patients from racial-ethnic minority groups.

Authors:  Nicholas J Carson; Andrew Vesper; Chih-Nan Chen; Benjamin Lê Cook
Journal:  Psychiatr Serv       Date:  2014-07       Impact factor: 3.084

2.  Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm.

Authors:  Laura Barrie Smith; Nihar R Desai; Bryan Dowd; Alexander Everhart; Jeph Herrin; Lucas Higuera; Molly Moore Jeffery; Anupam B Jena; Joseph S Ross; Nilay D Shah; Pinar Karaca-Mandic
Journal:  Int J Health Econ Manag       Date:  2020-04-30

3.  Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.

Authors:  Greta A Bushnell; Til Stürmer; Sonja A Swanson; Alice White; Deborah Azrael; Virginia Pate; Matthew Miller
Journal:  Psychiatr Serv       Date:  2015-11-16       Impact factor: 3.084

4.  A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills.

Authors:  Nicholas J Carson; Ana M Progovac; Ye Wang; Benjamin L Cook
Journal:  Depress Anxiety       Date:  2017-09-29       Impact factor: 6.505

5.  Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.

Authors:  Jamie Browning; Chi Chun Steve Tsang; Jim Y Wan; Marie A Chisholm-Burns; Samuel Dagogo-Jack; William C Cushman; Xiaobei Dong; Junling Wang
Journal:  J Am Pharm Assoc (2003)       Date:  2021-08-25

6.  Food and Drug Administration Safety Communication on the Use of Transvaginal Mesh in Pelvic Organ Prolapse Repair Surgery: The Impact of Social Determinants of Health.

Authors:  Jialin Mao; Bilal Chughtai; Said Ibrahim; Art Sedrakyan
Journal:  Female Pelvic Med Reconstr Surg       Date:  2021-01-01       Impact factor: 1.913

7.  The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.

Authors:  Kanika Anand; Ingrid Sketris; Ying Zhang; Adrian Levy; John-Michael Gamble
Journal:  Drugs Real World Outcomes       Date:  2017-12

8.  Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning.

Authors:  Benjamin L Cook; Ye Wang; Rajan Sonik; Susan Busch; Nicholas Carson; Ana M Progovac; Alan M Zaslavsky
Journal:  Health Serv Res       Date:  2019-02       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.